Evidence map›Paper›PMID 32568197›Full record

ReviewJournal of Alzheimer's disease : JAD2020

Towards a Redefinition of Cognitive Frailty.

Elisa Mantovani, Chiara Zucchella, Federico Schena, Maria Grazia Romanelli, Massimo Venturelli, Stefano Tamburin

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04912245 nacompletednot on this mapstarted 2021, after this paper: background citation

A Telehealth Advance Care Planning Intervention in Those With Mild Cognitive Impairment or Unrecognized Dementia (Tele Voice)

TypeinterventionalSponsorWake Forest University Health SciencesRan2021 to 2022Enrolled152ConditionsAdvance Care Planning, Telemedicine, Mild Cognitive Impairment, Unrecognized DementiaArmsTelehealth visit
NCT06797440 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of Dual Tasks of Digital Technology on Cognitive Function and Physical Activity in the Older Adults With Cognitive Frailty - A Randomized Controlled Trial

TypeinterventionalSponsorNational Taipei University of Nursing and Health SciencesRan2025 to 2026Enrolled100ConditionsCognitive FrailtyArmsDual tasks of digital technology
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Subjective Memory Complaints: A Conceptual Analysis.Journal of multidisciplinary healthcare · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Elisa MantovaniDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Chiara ZucchellaSection of Neurology, Department of Neurosciences, Verona University Hospital, Verona, Italy.
Federico SchenaDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Maria Grazia RomanelliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Massimo VenturelliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Stefano TamburinDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe progressive aging of the population will dramatically increase the burden of dementia related to Alzheimer's disease (AD) and other neurodegenerative disorders in the future. Because of the absence of drugs that can modify the neuropathological substrate of AD, research is focusing on the application of preemptive and disease-modifying strategies in the pre-symptomatic period of the disease. In this perspective, the identification of people with cognitive frailty (CF), i.e., those individuals with higher risk of developing dementia, on solid pathophysiological bases and with clear operational clinical criteria is of paramount importance. OBJECTIVE/

methodsThis hypothesis paper reviews the current definitions of CF, presents and discusses some of their limitations, and proposes a framework for updating and improving the conceptual and operational definition of the CF construct.

resultsThe potential for reversibility of CF should be supported by the assessment of amyloid, tau, and neuronal damage biomarkers, especially in younger patients. Physical and cognitive components of frailty should be considered as separate entities, instead of part of a single macro-phenotype. CF should not be limited to the geriatric population, because trajectories of amyloid accumulation are supposed to start earlier than 65 years in AD. Operational criteria are needed to standardize assessment of CF.

conclusionBased on the limitations of current CF definitions, we propose a revised one according to a multidimensional subtyping. This new definition might help stratifying CF patients for future trials to explore new lifestyle interventions or disease-modifying pharmacological strategies for AD and dementia.

Indexed as

AgingAlzheimer DiseaseAmyloidosisBiomarkersCognitionCognitive DysfunctionFrailtyHumansBiomarkersBiomarkerscognitive frailtydementiafrailtymild cognitive impairmentneuropathologysubjective cognitive impairment

Identifiers

PMID32568197
PMCPMC7504985
OpenAlexW3036459383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.